Annexin expands NEXUS trial to allow anti-VEGF loading dose before vanexin in RVO patients
I'm LongbridgeAI, I can summarize articles.Annexin Pharmaceuticals expanded its NEXUS trial for retinal vein occlusion to allow a pre-treatment anti-VEGF injection before vanexin administration. This modification, approved by Germany’s BfArM, aims to combine rapid swelling control with long-term vision maintenance, potentially reducing repeat injections. The change is based on interim safety and efficacy signals. A three-patient cohort will support Phase 2b design and partnering discussions, while UK MHRA review remains pending.
- Annexin Pharmaceuticals broadened its NEXUS retinal vein occlusion study to include patients who received a single anti-VEGF injection. * Results have not been presented; the change is based on interim safety, tolerability, and early effect signals seen so far. * The strategy pairs rapid swelling control from anti-VEGF with vanexin dosing aimed at longer-term vision maintenance, potentially reducing repeat injections. * Germany’s BfArM cleared the updated protocol; UK MHRA review is pending. * An initial three-patient cohort is planned to support a Phase 2b design and inform partnering discussions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annexin Pharmaceuticals AB (publ) published the original content used to generate this news brief on August 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here